ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab Proof-of-Concept…
- Topline data from the eblasakimab Phase 1b multiple-ascending-dose study will be presented during the “Late-breaking…
Read More...
Read More...